BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   113 News 
  • ||||||||||  Admelog (insulin lispro biosimilar) / Sanofi, BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia, Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
    Review, Journal:  Update on Biosimilar Insulins: A US Perspective. (Pubmed Central) -  Apr 10, 2021   
    Both Basaglar (insulin glargine) and Admelog (insulin lispro) have undergone extensive testing, and have gained significant use by patients in the US...We will also discuss challenges for prescribers and patients who are navigating this ever-changing landscape. These new regulations for biosimilar insulins will have ramifications for patients, healthcare providers, and third-party payers, though the direction and scope of these changes is unclear.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    [VIRTUAL] Effect of stratification factors and baseline postprandial glucose on glycemic control after treatment with ultra rapid lispro or Humalog: subgroup analyzes of PRONTO-T1D (Channel 1) -  Mar 21, 2021 - Abstract #DDG2021DDG_427;    
    In PRONTO-T1D, a phase 3, 26-week, treat-to-target study comparing URLi to Humalog in patients with type 1 diabetes (T1D) on a multiple daily injection regimen with insulin glargine or degludec, mealtime URLi was non-inferior to mealtime Humalog for change from baseline HbA1c and superior for PPG control with a similar safety profile to Humalog. Numerically, results suggest that basal insulin type, starting PPG, and starting HbA1c, but not prandial dosing plan, may influence the magnitude of the HbA1c improvement and / or hypoglycaemia risk reduction among patients treated with URLi compared to Humalog.
  • ||||||||||  BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
    [VIRTUAL] High Insulin Resistance in Pancreatic Adenocarcinoma (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1141;    
    Basic science research found that adrenomedullin, an amionopeptide, is up-regulated in patients with pancreatic cancer and causes insulin resistance in β Cells. Cancer theories also found about metabolic reprogramming and metabolic cross talk happens between pancreatic cancer and peripheral tissue, inhibiting cellular glucose intake and inducing insulin resistance.
  • ||||||||||  Piqray (alpelisib) / Novartis
    [VIRTUAL] A Case of Diabetic Keto Acidosis From Alpelisib (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1072;    
    She was bridged and subsequently transitioned to insulin glargine with insulin lispro sliding scale...Once hyperglycemia is detected, prompt initiation of oral hypoglycemic agent metformin (first line) or insulin therapy is recommended depending on the severity of the hyperglycemia...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    [VIRTUAL] Use of NPH insulin in a patient with uncontrolled type 2 diabetes on peritoneal dialysis () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_3588;    
    There is a paucity of evidence providing guidelines for the optimal management strategy in this patient population. However, the unique pharmacokinetic profile of NPH insulin may provide enhanced glucose control in this patient population over traditional long acting-rapid acting regimens as demonstrated in this case.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    [VIRTUAL] INSULIN ALLERGY IN A PATIENT WITH TYPE 1 DIABETES MELLITUS () -  Nov 21, 2020 - Abstract #ACAAI2020ACAAI_615;    
    She was subsequently started on mycophenolate mofetil and a brief course of oral corticosteroids with significant improvement in rash and tolerability of insulin administration.Discussion Evaluation of insulin reactions requires thorough evaluation of non-insulin components and underlying etiology of reaction. Our patient’s clinical history suggested a delayed-type hypersensitivity which is further supported by her clinical improvement with T-cell lymphocyte suppression.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Biosimilars and Novel Insulins. (Pubmed Central) -  Jun 9, 2020   
    Faster aspart is the first ultrafast-acting insulin. New upcoming clinical trials and more clinical experience with faster aspart will show the real potential of this new insulin.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] INSULIN PRICES IN CANADA, SAUDI ARABIA, AND THE US. () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1819;    
    The indexed price for insulin glulisine 100 units/ml vial was 42.2 in Saudi Arabia, 100.0 in Canada, and 548.4 in the US; insulin lispro 100 units/ml pen was 49.6 in Saudi Arabia, 100.0 in Canada, and 697.0 in the US; insulin Glargine 100 units/ml pen was 41.6 in Saudi Arabia, 100.0 in Canada, and 224.8 in the US; insulin detemir 100 units/ml pen was 35.0 in Saudi Arabia, 100.0 in Canada, and 263.5 in the US; Insulin degludec 100 units/ml pen was 63.8 in Saudi Arabia, 100.0 in Canada, and 380.6 in the US; insulin degludec 200 units/ml pen was 64.7 in Saudi Arabia, 100.0 in Canada, and 385.1 in the US. Prices of insulin products on January 1, 2020, were over 4 times higher in the US than in Canada, and over 8 times higher in the US than in Saudi Arabia.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Journal:  Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway. (Pubmed Central) -  Feb 7, 2020   
    Follow-on insulin products approved through the 505(b)(2) pathway are supported by robust efficacy and safety data. As new follow-on insulins are approved and the regulatory change that will occur with these products in 2020 approaches, formulary decisions and clinical policies (eg, substitution) will continue to be revisited.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Diagnosis of neonatal diabetes with rare PDX1-mutation (Green Room) -  Jan 4, 2020 - Abstract #WSMRF2020WSMRF_393;    
    The clinical course of neonatal diabetes depends on the genotype. In this case, the infant presented with persistent hyperglycemia requiring basal-bolus regimen, but the mild phenotype allowed the patient to be successfully weaned off insulin.
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    COMPARISON OF TWO PREGNANCIES OF A WOMAN WITH TYPE 1 DIABETES WITHOUT AND WITH AAPS (ANDROID ARTIFICIAL PANCREAS SYSTEM) SUPPORT (E-Poster Area) -  Dec 29, 2019 - Abstract #ATTD2020ATTD_318;    
    Methods A woman with 30 years of T1D underwent two subsequent pregnancies: Pregnancy one at age 35 using multiple daily injections (MDI) therapy (insulin glargine, Sanofi and insulin lispro, Eli-Lilly) with flash glucose monitoring (FGM; Abbott Libre Flash)...Conclusions AAPS in pregnant women with T1D can improve metabolic control at reduced risk of hypoglycaemia leading to substantially improved quality of life. Pregnant women with T1D are not willing to wait for commercially available closed loop systems.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Clinical, Review, Journal:  Understanding concentrated insulins: a systematic review of randomized controlled trials. (Pubmed Central) -  Sep 12, 2019   
    Clinical findings (HbA1c and hypoglycemia) and methodology (initiation and titration), patient factors (insulin experience and dosing requirements), and treatment characteristics (bioequivalence, potency, and device features) are important considerations. This overview of these and other factors provides essential information and guidance for using concentrated insulins in clinical practice.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Review, Journal:  Concentrated Insulins: History and Critical Reappraisal. (Pubmed Central) -  Jul 13, 2019   
    Although some clinicians only use concentrated insulin with obese and severely insulin resistant patients, other patients would also benefit from the reduced injection volume associated with concentrated insulins, or the modified time action profile of some concentrated insulins. This review aims to enhance understanding of the historic development, and the safe and effective use of concentrated insulins in clinical practice.
  • ||||||||||  BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
    Trial completion:  A Trial to Investigate the Dose-linearity of BioChaperone (clinicaltrials.gov) -  Jan 10, 2018   
    P1,  N=32, Completed, 
    This review aims to enhance understanding of the historic development, and the safe and effective use of concentrated insulins in clinical practice. Recruiting --> Completed
  • ||||||||||  BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
    Trial completion, Trial primary completion date:  A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone (clinicaltrials.gov) -  Jun 29, 2017   
    P1,  N=36, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jun 2017
  • ||||||||||  BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
    Enrollment open:  A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone (clinicaltrials.gov) -  Oct 25, 2016   
    P1,  N=36, Recruiting, 
    Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jun 2017 Not yet recruiting --> Recruiting
  • ||||||||||  BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
    Trial completion:  Postprandial Blood Glucose Control With BioChaperone (clinicaltrials.gov) -  Nov 8, 2015   
    P1,  N=28, Completed, 
    Recruiting --> Completed Recruiting --> Completed